Clinical Implications of Bacteremia Caused by Non-<i>baumannii Acinetobacter</i> Compared with Those of <i>Acinetobacter baumannii</i> Bacteremia.

ABSTRACT: Objectives: This study aimed to compare clinical characteristics, antimicrobial susceptibility, and 28-day mortality between patients with Acinetobacter baumannii bacteremia (ABB) and non-baumannii Acinetobacter bacteremia (NBAB) after rapid matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) species identification. Methods: We retrospectively reviewed the clinical data of adult ABB and NBAB patients over >7 years. Multivariate logistic regression was used to identify the risk factors for 28-day mortality. Results: Of 273 episodes of Acinetobacter species bacteremia, 224 (82.1%) were ABB and 49 (17.9%) were NBAB. NBA isolates were predominantly A. nosocomialis (49%), with smaller proportions of A. bereziniae, A. junii, A. ursingii, and others. The primary sites of infection in NBAB cases were the intra-abdomen, urinary tract, intravascular catheters, and lungs. While only 4.0% of A. baumannii isolates were susceptible to carbapenem, 87.8% of non-baumannii Acinetobacter isolates were susceptible. Multivariate analysis revealed that low carbapenem resistance was independently associated with NBAB. Additionally, a higher Pitt bacteremia score, septic shock, continuous renal replacement therapy, inappropriate empirical antibiotic therapy, and thrombocytopenia were independent risk factors for the 28-day mortality in patients with ABB. Conclusions: Although less common than ABB, NBAB cases are increasing and exhibit lower carbapenem resistance. Rapid MALDI-TOF MS identification enables timely and appropriate antibiotic treatment. The key factors driving the 28-day mortality include illness severity, septic shock, renal replacement therapy, inappropriate antibiotics, and thrombocytopenia, highlighting the need for early risk assessments and tailored management. Ongoing surveillance and species-specific strategies are essential for combating resistant Acinetobacter infections.

SUBMITTER: Suh JW 

PROVIDER: S-EPMC12467366 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature